Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

NCT03693170 PHASE2 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of the combination of study drugs encorafenib, binimetinib and cetuximab in patients who have BRAF V600 mutant metastatic colorectal cancer and have not received any prior treatment for their metastatic disease.

Details

Lead sponsor	Pierre Fabre Medicament
Phase	PHASE2
Status	COMPLETED
Enrolment	95
Start date	Thu Jan 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Apr 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions

• encorafenib
• Binimetinib
• Cetuximab

Countries

France, Italy, Japan, Netherlands, Belgium, Austria, United Kingdom, United States, Spain